XML 39 R29.htm IDEA: XBRL DOCUMENT v3.25.1

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Provisions for Sales and Allowances

A rollforward of the Company’s provisions for sales discounts and allowances is as follows:

		March 31, 2025
(In thousands)		Contractual Adjustments(1)				Discounts(2)				Product Returns				Other				Total
Beginning balance — December 31, 2024		$	228,978			$	43,645			$	50,507			$	13,297			$	336,427
Current provisions relating to sales in current year			123,300				91,264				6,392				19,543				240,499
Adjustments relating to prior years			(11,311	)			—				(901	)			—				(12,212	)
Payments relating to sales in current year			(5,713	)			(81,201	)			—				(11,839	)			(98,753	)
Payments relating to sales in prior years			(120,893	)			(20,793	)			(3,087	)			(11,244	)			(156,017	)
Ending balance — March 31, 2025		$	214,361			$	32,915			$	52,911			$	9,757			$	309,944

1.“Contractual Adjustments” include “Medicaid Rebates” and “Medicare Part D” accruals

2.“Discounts” include “Chargebacks” and “Product Discounts”

Schedule of Revenue Related Reserves Included in Consolidated Balance Sheets

Total revenue-related reserves as of March 31, 2025 and December 31, 2024 included in the accompanying consolidated balance sheets are summarized as follows:

		March 31,				December 31,
(In thousands)		2025				2024
Reduction of accounts receivable		$	14,993			$	22,031
Components of accrued sales discounts, allowances and reserves			249,795				272,452
Components of other long-term liabilities			45,156				41,944
Total revenue-related reserves		$	309,944			$	336,427

Schedule of Contract Assets and Contract Liabilities

Total contract assets at March 31, 2025 were as follows:

(In thousands)		Contract Assets
Contract assets at December 31, 2024		$	4,990
Additions			3,049
Transferred to receivables, net			(4,990	)
Contract assets at March 31, 2025		$	3,049

Total contract liabilities at March 31, 2025 were as follows:

(In thousands)		Contract Liabilities
Contract liabilities at December 31, 2024		$	1,249
Additions			1,313
Amounts recognized into revenue			(953	)
Contract liabilities at March 31, 2025		$	1,609

Product sales, net

Schedule of Disaggregation of Revenues

During the three months ended March 31, 2025 and 2024, the Company recorded product sales, net, as follows:

		Three Months Ended March 31,
(In thousands)		2025				2024
VIVITROL			100,996			$	97,659
ARISTADA and ARISTADA INITIO			73,475				78,870
LYBALVI			70,022				57,007
Total product sales, net		$	244,493			$	233,536

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the three months ended March 31, 2025 and 2024, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:

		Three Months Ended March 31, 2025
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	17,745			$	17,745
VUMERITY			5,975				21,858				27,833
RISPERDAL CONSTA			9,115				14				9,129
Other			2,237				5,073				7,310
		$	17,327			$	44,690			$	62,017

		Three Months Ended March 31, 2024
(In thousands)		Manufacturing Revenue				Royalty Revenue				Total
Long-acting INVEGA products(1)		$	—			$	62,673			$	62,673
VUMERITY			12,124				19,130				31,254
RISPERDAL CONSTA			2,595				124				2,719
Other			15,311				4,876				20,187
		$	30,030			$	86,803			$	116,833

(1)“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).

X

- Definition

Revenue related reserves included in consolidated balance sheets.

+ References

No definition available.

+ Details

Name:	alks_RevenueRelatedReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix:	alks_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 326
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479319/326-20-50-13

+ Details

Name:	us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=alks_ManufacturedProductAndRoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: